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Anaemia is associated with adverse outcomes including early death in the first year of anti-
retroviral therapy (ART). This study reports on the factors associated with persistent anae-
mia among HIV-infected patients initiating ART in the Democratic Republic of Congo (DR
Congo).
Methods
We conducted a retrospective cohort study and analyzed data from patients receiving HIV
care between January 2004 and December 2012 at two major hospitals in Goma, DR
Congo. Haemoglobin concentrations of all patients on ART regimen were obtained prior to
and within one year of ART initiation. A logistic regression model was used to identify the
predictors of persistent anaemia after 12 months of ART.
Results
Of 756 patients, 69% of patients were anaemic (IC95%: 65.7–72.3) at baseline. After 12
months of follow up, there was a 1.2 g/dl average increase of haemoglobin concentration
(P < 0.001) with differences depending on the therapeutic regimen. Patients who received
zidovudine (AZT) gained less than those who did not receive AZT (0.99 g/dl vs 1.33 g/dl; p<
0.001). Among 445 patient who had anaemia at the beginning, 33% (147/445) had the con-
dition resolved. Among patients with anaemia at ART initiation, those who did not receive
cotrimoxazole prophylaxis before starting ART(AOR 3.89; 95% CI 2.09–7.25; P < 0.001)
and a AZT initial regimen (AOR 2.19; 95% CI 1.36–3.52; P < 0.001) were significantly at risk
of persistent anaemia.
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Conclusions
More than two thirds of patients had anaemia at baseline. The AZT-containing regimen and
absence of cotrimoxazole prophylaxis before starting ART were associated with persistent
anaemia 12 months, after initiation of treatment. Considering the large proportion of patients
with persistence of anaemia at 12 months, we suggest that it is necessary to conduct a
large study to assess anaemia among HIV-infected patients in Goma.
Background
Anaemia during infection with the human immunodeficiency virus (HIV) may have multiple
causes [1]. The prevalence of anaemia in people with acquired immunodeficiency syndrome
(AIDS) has been estimated between 63 to 95% [2–3].
The incidence of anaemia increases with the progression of HIV infection [4–6]. Anaemia is
also a known feature of certain opportunistic infections, includingas tuberculosis, atypical
mycobacteria, microcystosis, cryptococcus and parvovirus B19 [7]. It has been suggested that
the use of a regimen containing zidovudine (AZT) at the initiation of antiretroviral therapy
(ART) is associated with the incidence of anaemia, with bone marrow toxicity being postulated
as the main underlying mechanism [8]
In addition to reduced physical functioning and quality of life caused by anaemia, its pres-
ence at the initiation of ART has been associated with HIV disease progression and mortality
[4, 9–14]. Indeed, in the Euro SIDA cohort, patients with severe anaemia at baseline had 13
times greater risk of death during the first year of ART than patients with a normal haemoglo-
bin (Hb) concentration [10], similar findings having been reported from Tanzania, Côte
d'Ivoire, South Africa, Malawi and the Democratic Republic of Congo (DR Congo) [9, 13–15].
There has been a decline in the prevalence of anaemia and an increment in mean CD4+ T
cell count among HIV infected patients after ART initiation, as seen from studies carried out in
Africa, such as Adane’s study [16]. Research in Europe and North America has also shown that
ART itself can be an effective treatment of anaemia associated with HIV infection [7, 10, 17],
just as improvement of haemoglobin concentration occurs with ART [9, 14]. However, only a
few studies have looked at the changes of haemoglobin concentration among patients on ART
in resource-limited settings, and whether these changes may vary with the ART regimen.
Given the number of patients on ART in this rural area selected for study in the DR Congo, we
believe that a better understanding of the role of anaemia in HIV treatment is critical to devel-
oping strategies to reduce morbidity and improve survival on ART.
Mortality is higher in the first year of ART, with anaemia being cited as one of the factors of
death among patients receiving ART [10, 15]. The present study has been aimed at determining
the predictors of persistence of anaemia during the first year of treatment with ART among
HIV patients in two hospitals in Goma (DR Congo).
Methods
Study site and design
We conducted a retrospective cohort study on patients from two major hospitals, the Virunga
hospital and Goma provincial referral hospital (GPRH) in Goma. This is a city located in the
eastern part of DR Congo that has been affected by civil war for many years, and which has a
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prevalence of HIV of 0.9% [18]. HIV care and treatment services at the Virunga hospital and
GPRH have provided ART free of charge since 2004.
Study population
We describe the baseline haematological profile in a cohort of treatment-naïve individuals
aged 15 years or older. These patients were enrolled in the HIV care and treatment programme
at the Virunga hospital and GPRH between January 2004 and December 2012.
Treatment, monitoring and information collected. In DR Congo, including Goma, ART
was initiated in accordance with guidelines from the World Health Organization (WHO) and
the National AIDS Control Program [19–20]. First-line treatment comprised Stavudine (D4T)
or AZT, combined with Lamivudine (3TC), and either Nevirapine (NVP) or Efavirenz (EFV).
Regimen choice was subject to availability, with use of a generic fixed-dose combination of
D4T, 3TC and NVP whenever possible. Patients were seen by a clinical officer every 3 months.
Their CD4 cell and full blood (including haemoglobin) counts were scheduled every 3 months
as part of a routine follow- up.
Anaemia was defined according to the WHO guidelines, as a haemoglobin concentration
of<12 g/dl for women and<13 g/dl for men [21]. We classified the anaemia as mild (11–11.9
g/dl for women and 11–12.9 g/dl for men), moderate (8–10.9 g/dl) and severe (<8 g/dl in both
genders).
The following informations were collected: socio-demographic characteristics (age, gender,
marital status and education), clinical characteristics (therapeutic regimen, WHO clinical stage
of disease) and biological characteristics (CD4 count, haemoglobin at baseline and 12 months
after treatment initiation). The outcome, one year after the start of ART was the persistence of
anaemia. Loss to follow-up was defined as failure to return to the centre 3 months after the last
clinic visit. Mortality was ascertained through family or hospital report as well as, active
tracing.
All patients who were anaemic at the time of ART initiation and had a follow-up haemoglo-
bin measurement 12 months later were included in the analysis.
Statistical analysis
In general, we applied the value closest to starting ART as the baseline value. Chi-square tests
were used to study the association of baseline characteristics with severity of anaemia at base-
line. The mean of the haemoglobin concentration and its confidence interval were calculated.
Paired samples t-tests were used to compare haemoglobin concentration before and 12 months
after ART initiation. Overall changes in haemoglobin concentration on treatment were further
examined by stratifying results by sex (male versus female) at treatment initiation using the t-
test. The paired t-test was used to compare the haemoglobin gain over 12 months between the
group receiving AZT and those not receiving AZT. McNemar’s test was used to compare the
proportion of patients with anaemia at the beginning and end of the first 12 months on ART.
A logistic regression model was used to identify predictors of persistent anaemia after 12
months of ART among anaemic patients at treatment initiation. Gender, age, stage of disease,
ART regimen, cotrimoxazole prophylaxis and CD4 count at baseline were entered into a logis-
tic model to find the factors associated with the persistence of anaemia. Data were analysed
with SPSS version 21.0 for Windows. All tests were two-sided and the level of significance was
set at P< 0.05.
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Ethical Statement
This study was approved by the institutional review board ethics committee for research sub-
jects at Kinshasa University School of Public Health. Written informed consent was not given
by participants for their clinical records to be used in this study, but patient records/informa-
tion was anonymized and de-identified prior to analysis. (No App: ESP/CE/034/14 of
27.08.2014).
Results
Patient characteristics at enrollment
A total of 844 HIV patients were enrolled in the HIV program between January 1, 2004, and
December 15, 2012. We excluded those who had not yet been on ART for 12 months (79
patients) and those with missing Hb values at enrolment (88 patients). Overall, the excluded
patients were similar to those who were kept in the analysis in terms of age (mean 39.51± 9.79
years) and gender (63.9% female) distributions. Among 445 patients who had anaemia at the
beginning, 33% (147/445) had resolution of anaemia (See Fig 1).
A total of 756 HIV-infected subjects who were eligible for this study and included in this
study (Fig 1). The mean age was 38.76 years (standard deviation [SD] 9.96) and 493 patients
(66.5%) were women. At baseline, 109 patients (14.6%) had clinical AIDS (WHO stage 4), 418
(56.0%) had WHO stage 3, 164 (22%) had WHO stage 2, and 54 (7.4%) had WHO stage 1 dis-
ease. Sixty nine percent of patients were anaemic (95% CI: 65.7–72.3), of which 45.1, 17.7, and
6.5% had mild, moderate, and severe anaemia, respectively.
Fig 1. Study flow of participants in two different HIV treatment centers at Goma, in the Democratic
Republic of Congo.
doi:10.1371/journal.pone.0140240.g001
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Table 1 gives an overview of patient characteristics at enrolment and associations with anae-
mia. Male gender, clinical AIDS (stage of disease) and low CD4 count were all significantly
associated with anaemia at enrolment.
Haemoglobin evolution during antiretroviral treatment
Of the 656 patients with documented haemoglobin concentrations at initiation of ART and
the end of the first 12 months, 67.3% (445/656) were anaemic at initiation. Twelve months
later, the proportion of patients with anaemia was reduced to 43% (308/656 McNemar’s test,
p< 0.001) (See S1 Table, which shows evolution of proportion of anaemia at the time of initia-
tion of ART and 12 months later).
Table 1. Patient characteristics and degree of anaemia at enrolment.
Overall (n) No anaemia Mild anaemia Moderate anaemia severe anaemia
All 756(100) 228(30.2) 201(26.6) 278(36.8) 49(6.5)
Age (years)*
 38 372(49.2) 109(47.8) 92(45.8) 154(55.4) 17(34.7)
> 38 384(50.8) 119(52.2) 109(54.2) 124(44.6) 32(65.3)
Gender
male 248(32.8) 64(28.1) 95(47.3) 65(23.4) 24(49.0)
female 493(65.2) 162(71.1) 97(48.3) 209(75.2) 25(51.0)
missing 15(2.0) 2(0.9) 9(4.5) 14(1.4) 0(0.0)
Education level atteined
None 287(38.0) 87(38.2) 70(34.8) 110(39.6) 20(40.8)
primary 249(32.9) 81(35.5) 72(35.8) 86(30.9) 10(20.4)
Secondary or higher 197(26.1) 55(24.1) 53(26.4) 72(25.9) 17(34.7)
missing 23(3.0) 5(2.2) 6(3.0) 10(3.6) 2(4.1)
Marital status
married/Cohabitating 384(50.8) 128(56.1) 112(55.7) 120(43.2) 24(49.0)
Single/Divorced/separated/widow(ed) 366(48.4) 99(43.4) 87(43.3) 156(56.1) 24(49.0)
missing 6(0.8) 1(0.4) 2(1.0) 2(0.7) 1(2.0)
stage of desease (WHO)
StageI or II 219(29.0) 75(32.9) 54(26.9) 77(27.7) 13(26.5)
Stage III 418(55.3) 131(57.5) 119(59.2) 143(51.4) 25(51.0)
Stage IV 109(14.4) 19(8.3) 25(12.4) 54(19.4) 11(22.4)
missing 10(1.3) 3(1.3) 3(1.5) 4(1.4) 0(0.0)
CD4 (cells/μl)
< 50 154(20.4) 39(17.1) 38(18.9) 61(21.9) 16(32.7)
50 to 199 337(44.6) 97(42.5) 93(46.3) 124(44.6) 23(46.9)
 200 242(32.0) 86(37.7) 61(30.3) 88(31.7) 7(14.3)
missing 23(3.0) 6(2.6) 9(4.5) 5(1.8) 3(6.1)
Cotrimoxazole
no 618(81.7) 192(84.2) 159(79.1) 226(81.3) 41(83.7)
yes 109(14.4) 30(13.2) 33(16.4) 41(14.7) 5(10.2)
missing 29(3.9) 6(2.6) 9(4.5) 11(4.0) 3(6.1)
Haemoglobin, mean ± SD 10,9 ± 2,0 13.2 ± 1.2 11.5 ± 0.5 9.6 ± 0.8 6.9 ± 0.9
SD: standard deviation
*: median age was 38 years
doi:10.1371/journal.pone.0140240.t001
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At ART initiation the mean haemoglobin was 11.06 g/dl (SD 2.06), with women having a
lower haemoglobin than men (10.83 vs 11.28; p = 0.010). After receiving ART for 12 months,
the mean haemoglobin increased to 12.31 g/dl (SD 1.96) (See S2 Table, which shows haemoglo-
bin evolution during antiretroviral treatment), an average increase of 1.2 g/dl (p< 0.001). The
average differed depending on the therapeutic regimen: patients who received AZT gained less
than those who did not receive AZT (0.99 g/dl vs. 1.33 g/dl; p< 0.001) (See S2 Table).
Predictors of persistent anaemia among 445 HIV-infected adults
anaemic at ART initiation
Two hundred thirty-two patients who did not have anaemia at the time of ART initiation, and
79 patients who were anaemic at enrolment and received ART for less than 12 months were
excluded in the logistic regression model. Among patients who were anaemic at ART initiation,
the absence of cotrimoxazole prophylaxis prior to initiating ART [adjusted odds ratio (AOR)
3.89; 95% CI 2.09–7.25; P< 0.001] and an AZT-containing initial regimen (AOR 2.19; 95% CI
1.36–3.52; P< 0.001) were significantly associated with the persistence of anaemia (Tables 2
and 3). The database for this manuscript is available as an additional supporting information
(S1 and S2 Datasets).
Discussion
In this study 69% of HIV-infected subjects had anaemia at the time they had been enrolled in
HIV care. Women were more likely than men to be anaemic. Patients who were not on
Table 2. Bivariate analysis of factors associated with persistent anaemia.
Persistent anaemia Crude OR (95%CI) p-value
yes no
Age (years)*
-  38 153(67.4) 74(32.6) 1
- > 38 145(66.5) 73(33.5) 0.96 (0.65–1.43) 0,842
Gender
- female 196(65.8) 101(34.2) 1
- male 96(69.6) 42(30.4) 1.19 (0.77–1.84) 0,434
WHO stage
- Stage I or II 83(65.4) 44(34.6) 1
- Stage III 155(64.9) 84(35.1) 0.98 (0.62–1.54) 0,924
- Stage IV 55(75.3) 18(24.7) 1.62 (0.85–3.09) 0,143
CD4 (cells/μl)
-  200 95(69.3) 42(30.7) 1
- 50 to 199 136(66.3) 69(33.7) 0.87 (0.55–1.39) 0,561
- < 50 62(68.9) 28(31.1) 0.98 (0.55–1.74) 0,942
Cotrimoxazole
- yes 25(43.1) 33(56.9) 1
- no 259(70.6) 108(29.4) 3.17 (1.80–5.58) < 0,001
Regimen
- Without AZT 161(60.3) 106(39.7) 1
- With AZT 134(77.9) 38(22.1) 2.32 (1.50–3.59) < 0,001
*: Median age was 38 years
doi:10.1371/journal.pone.0140240.t002
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cotrimoxazole prophylaxis before ART initiation and those on an AZT-containing regimen
were more likely to have persistent anaemia 12 months after initiation of ART. Among 445
patients with anaemia from the start, 33% had resolution of anaemia.
Haemoglobin concentration increased significantly in patients who received ART; on aver-
age the haemoglobin increased 1.2 g/dl over the first 12 months. European and North Ameri-
can studies reported that ART is associated with resolution of HIV-associated anaemia [10,
17]. More recently, similar findings come from work in sub-Saharan Africa; in rural Uganda
found it was shown that the mean haemoglobin increased from 11.3 g/dl at baseline to 12.8 g/
dl after 12 months on ART [22]. However, the magnitude of the increased haemoglobin might
vary depending on its baseline concentration and the degree of immunodeficiency. Our study
is consistent with others showing that HIV-associated anaemia can be reversed with the use of
ART as in the research carried out by Moore et al. (17). To a certain degree indicates that HIV-
associated anaemia in our setting is mainly the result of factors related to the HIV infection
itself, such as chronic inflammation and opportunistic infections, rather than tropical diseases
or specific environmental factors. Sixty-seven percent of patients having persistent anaemia at
12 months represents a large proportion, the possible causes being poor nutrition, drug toxicity
and parasitic diseases. But we did not measure such data, which is one of the limitations of the
study.
Although we observed an increase in haemoglobin over the 12 months follow up, differen-
tials exist depending on the ART regimen, patients on AZT-based regimen experiencing a
lower increase in haemoglobin compared to those on D4T-based regimen. Similar findings
were reported from Uganda where anaemic patients on D4T- containing regimens had a signif-
icantly larger increase in haemoglobin than those on AZT-based regimens [23]. The same pat-
tern was shown in a meta-analysis of six randomized trials, in which the mean haemoglobin
concentration was 0.8 g/dl lower in patients who received AZT than those who received D4T
after 48 weeks on ART [4]. However, the trend of improving haemoglobin concentration
despite initiating an AZT-containing regimen has been similarly documented in other studies
from Ugandan [23] and South African cohorts [8, 24].
Table 3. Multivariate analysis of factors associated with persistent anaemia.
Crude OR (95%CI) p Adjusted OR (95%CI) p
Age (year)
- > 38 (vs  38) 0.96 (0.65–1.43) 0.842 0.94 (0.60–1.47) 0.793
Gender
- male(vs female) 1.19 (0.77–1.84) 0.434 1.14 (0.69–1.85) 0.609
WHO stage
- Stage III(vs stage I or II) 0.98 (0.62–1.54) 0.924 0.83 (0.49–1.39) 0.474
- Stage IV(vs stage I or II) 1.62 (0.85–3.09) 0.143 1.59 (0.76–3.33) 0.215
CD4(cells/μl)
- 50 to 199(vs  200) 0.87 (0.55–1.39) 0.561 1.21 (0.72–2.02) 0.468
- < 50(vs  200) 0.98 (0.55–1.74) 0.942 1.22 (0.64–2.33) 0.555
Cotrimoxazole
- no (vs yes) 3.17 (1.80–5.58) < 0.001 3.89 (2.09–7.25) <0.001
Regimen
- with AZT(vs without AZT) 2.32 (1.50–3.59) < 0.001 2.19 (1.36–3.52) 0.001
We have introduced in the model Age, Gender, WHO stage, CD4, Cotrimoxazole and regimen.
doi:10.1371/journal.pone.0140240.t003
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We also found that persistent anaemia was associated with ART regimen and chemopro-
phylaxis of cotrimoxazole. Patients who had an initial AZT-containing regimen were more
likely to have persistent anaemia, which is in line with a previous cohort study in a rural hospi-
tal in Tanzania showing that the majority of patients who were anaemic at the time of ART ini-
tiation had significantly increased haemoglobin levels over the initial 12 months of ART.
However, patients on AZT-based regimens had more risk of persistent anaemia [25]. There is a
widely established link between the use of AZT and anaemia through myelo suppression [26,
27]. AZT can inhibit bone marrow activity, which leads to decreased production of blood cells
and platelets [28, 29]. Although, the association between AZT use and anaemia is well docu-
mented [25–31], its clinical significance remains under debate. The threshold defining anaemia
and study designs have differed in research methods of assessing the link between anaemia and
ART regimens. Indeed the Human Immunodeficiency Virus Epidemiology Research Study
[32] showed that, although the use of AZT was associated with an increased risk of anaemia
(defined as a haemoglobin concentration of<12 g/dl) in the pre-HAART era (1993–1996), use
of AZT during the HAART era (1996–2000) was not significantly associated with anaemia. In
contrast, the Women’s Interagency HIV Study recorded the presence of anaemia (defined as a
haemoglobin concentration of<10 g/dl or a physician's diagnosis) in 41.6% of subjects receiv-
ing AZT compared with 34.3% in those not receiving AZT [33].
Our results also support findings that ART improves haemoglobin regardless of the regimen
type (AZT containing versus non-AZT containing) and the degree of immuno-suppression;
however, correction of anaemia does not have the same magnitude depending on the therapeu-
tic regimen received by the patient (AZT-based vs non- AZT-based). These results underscore
the possible caveats of AZT, and suggest that other drugs might be preferable in anaemic
patients, especially in countries such as DR Congo where anaemia is endemic, and probably
related to malaria, intestinal parasites, malnutrition and other causes. The 2013 revision of the
WHO guidelines recommended tenofovir (TDF) in combination with 3TC or FTC and a non-
nucleoside reverse transcriptase inhibitor as the first regimen option in individuals initiating
ART unless contraindicated [34].
An unexpected finding was the negative association between the prescription of cotrimoxa-
zole and anaemia. Its use is known to be associated with aplastic anaemia or immune-mediated
destruction of specific populations of blood cells [35]; but our patients who were on cotrimoxa-
zole prior to initiating ART were less likely to have anaemia at baseline, and less likely to be
anaemic after 12 months. We assume that the protective effect of cotrimoxazole in preventing
opportunistic conditions such as the Mycobacterium avium complex [36], bacterial septicemia,
or other conditions well known to cause anaemia as a result of the chronic inflammation pro-
cess, could have outweighed the risk of cotrimoxazole in inducing anaemia. Management of
anaemia in settings with a high prevalence of HIV should always include an HIV test, and ART
should be initiated taking into account other local causes of anaemia. Our study suggests that
this would be sufficient to correct the anaemia in most subjects, and that additional test to
identify patients in whom additional treatment (such as iron supplementation or oxidative
stress correction) might be required.
Regarding several limitations in the present study, the first is related to the technique used
to collect data. Indeed, with the review of patient records, some information may have been
recorded with little rigor or accuracy. Second, we did not take into account other factors such
as adherence to treatment, transfusion history and the presence of co-morbidities (nutritional
status, HIV-tuberculosis co-infection, intestinal parasites, microcystosis, malaria etc.). Never-
theless, this study has the advantage of being among the few to document factors associated
with persistent anaemia during the first year of ART not only in the DR Congo but in an area
with ongoing conflict for several years.
Predictors of Persistent Anemia
PLOS ONE | DOI:10.1371/journal.pone.0140240 October 16, 2015 8 / 11
Conclusion
Over two-thirds of patients had anaemia at baseline. An AZT-containing regimen and absence
of cotrimoxazole prophylaxis before starting ART were associated with persistent anaemia 12
months after initiation of treatment. Considering the large proportion of patients with persis-
tence of anaemia at 12 months, we suggest that it is necessary to conduct a large study to assess
the anaemia among HIV-infected patients in Goma.
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